 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase3 Double-Blind, Randomized, Placebo-Controlled SUMMIT StudyDURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company...

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 65th Annual Scientific Meeting

The closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
read more...

Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, TESS, NATI, STSA SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, TESS, NATI, STSA PR Newswire NEW YORK, May 25, 2023 NEW YORK, May 25, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, TESS, NATI, STSA

NEW YORK, May 24, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the M&A Class Action Firm), a national securities firm ratedTop 50in the 2018-2021 ISS Securities Class Action Services Report and headquartered at theEmpire ...

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - STSA, CHRA, MYBF, ROCC

NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: TESSCO Technologies Incorporated (NASDAQ: TESS)s...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, NATI, STSA, CHRA

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA PR Newswire NEW YORK, May 18, 2023 NEW YORK, May 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA

January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike ...

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the M&A Class Action Firm), a national securities firm ratedTop 50in the 2018-2021 ISS Securities Class Action Services Report and headquartered at theEmpire ...

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - MGTA, STSA, ROCC, CVT

JonesTrading analyst Sean Kim PhD maintained a Hold rating on Satsuma Pharmaceuticals (STSA Research Report) today. The companys shares closed l... JonesTrading analyst Sean Kim PhD maintained a Hold rating on Satsuma Pharmaceuticals (STSA &#8211...

JonesTrading Sticks to Its Hold Rating for Satsuma Pharmaceuticals (STSA)

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Satsuma Pharmaceuticals, Inc. (Satsuma) (NasdaqGM: STSA) to Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the proposed...

SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Satsuma Pharmaceuticals, Inc. - STSA

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Watchers	2,579
52-Wk Low	$0.59
52-Wk High	$8.08

Market Cap	$36.47M
52-Wk High	$8.08
52-Wk Low	$0.59

Current Price	$1.10
Prev Close	$1.11
Open	$1.09
Dividend Yield	0.00%
50-Day Moving Average	$0.9776
Beta	1.75
Avg. Volume	460,323.73
PE Ratio	-0.55

52-Week High	$8.08
52-Week Low	$0.59
Market Capitalization	$36.47M
EPS	-$2.00
Price to Book	0.97
Revenue Per Employee	N/A
Enterprise Value/EBITDA	0.34

STSA Satsuma Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals